Advised Clinician Holdings on its investment round to raise approx. US$2.4m from NZ investors and Australian and Singapore VCs.
Advised Massey University on the sale of its ‘Ferri Pro’ technology (which combats iron deficiency) to Nestle.
Advised the investor consortium in relation to their NZ$15m investment in leading medical cannabis start-up, Helius Therapeutics.
Acted for Fergus Software in relation to aggregate investments of $A3.5m by an Australian venture capital fund and a large Australian corporate.
Andrew was appointed to the board of high growth financial services company Enable-Me – www.enableme.co.nz
Acted for Evergreen Capital (a New York based private equity firm) on the acquisition of the Wormald Group of companies in Australia from NYSE listed Tyco International, (which included acquisition of the Wormald brand worldwide and the National Fire Service (NSF) Group). McCullough Robertson (Adrian Smith) provided local support. See attached announcement from the Wall […]
Acted for the shareholders of The New Zealand School of Food Hygiene Limited and related companies (also known as Burwater Pacific group) on the sale of those companies to US buyer, NSF International. See attached announcement
Acted for the shareholders of NZ Tertiary Education Group (otherwise known as Cornerstone Group) in respect of the sale of that group of companies to Aspire2 Group, (ultimately controlled by leading Australian private equity firm, Archer Capital), as part of the roll-up and sale of 5 privately owned education groups. Also acted for the same […]
Acted for Four Seasons Pets in respect of the sale of its business to PETstock (a leading Australian operator).
Represented Massey Ventures in connection with the sale of the New Zealand Veterinary Pathology (NZVP) business to a wholly owned subsidiary of IDEXX Laboratories Inc (a US listed company and leading provider of veterinary diagnostic services globally). My involvement included an active role in the commercial negotiations and representing Massey Ventures (as a 36% shareholder) […]